Researchers using stem cells must work to make their treatments safer after a 17 year-old boy with a rare genetic disease in 2001 was cured with an embryonic stem cell transplant in Moscow, but then developed benign brain and spinal tumors four years later. According to ‘Plos Medicine’ magazine, Israeli doctors removed cancer from the boy, the tumors developed due to a stem cell treatment that he received.
The first operations have been successfully performed at Seriate Hospital (Bergamo) using autologous stem cell transplants to rebuild a part of the breast after removing a tumor. The technique used in the operation is known as ‘lipofilling’, which calls for some of the patient’s abdominal fat to be removed in a procedure similar to liposuction. The fat is then purified and manipulated in the laboratory to concentrate stem cells as much as possible, then they are transplanted into the portion of the breast that has been removed to eliminate the cancer.
Image via Wikipedia
Western Pennsylvania Cancer Institute’s Dr. Entezam Sahovic: We are hopeful that this new technology will enable us to help more patients in need of transplants.
A joint venture between Gamida Cell and Teva Pharmaceutical Industries Ltd. will carry out a study at Western Pennsylvania Hospital (WPH). WPH is currently enrolling patients for the study.
The ExCell study will assess the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal registration study.
StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood
Stem Cell Research Provides Help for Breast Reconstruction
Irene MacKenzie had a lumpectomy for her early stage breast cancer leaving her with a hollow in her breast. The lumpectomy took care of the cancer, but what about her breast? Well, Irene was the first person in Britain to reap the benefits of Stem Cell […]
An international team of researchers led by renowned stem cell scientist Professor Martin Pera has discovered a novel marker that plays an important role in our understanding of how cancer develops in the liver, pancreas and oesophagus.
The study, published in the journal Stem Cell, adds to our understanding of the role of stem and next stage progenitor cells in tissue regeneration and in the diagnosis and treatment of cancer.
While stem cells are known to reside in organs such as the liver and pancreas, they are difficult to isolate. The new findings show that an antibody developed by the team